Legalization, Decriminalization & Medicinal Use of Cannabis: A Scientific and Public Health Perspective

by Dragan M. Svrakic, MD, Patrick J. Lustman, PhD, Ashok Mallya, MD, Taylor Andrea Lynn, PhD, Rhonda Finney, RN & Neda M. Svrakic

Abstract
Empirical and clinical studies clearly demonstrate significant adverse effects of cannabis smoking on physical and mental health as well as its interference with social and occupational functioning. These negative data far outweigh a few documented benefits for a limited set of medical indications, for which safe and effective alternative treatments are readily available. If there is any medical role for cannabinoid drugs, it lies with chemically defined compounds, not with unprocessed cannabis plant. Legalization or medical use of smoked cannabis is likely to impose significant public health risks, including an increased risk of schizophrenia, psychosis, and other forms of substance use disorders.

Introduction
In recent years, there has been a strong pressure on state legislatures across the US to legalize or decriminalize use and possession of specified amounts of cannabis and/or to pass laws that allow smoking of crude cannabis plant (also known as marijuana, weed, Mary Jane, pot, reefer, ganja, joint and grass) for prescribed medical purposes (so called “medical marijuana”). Advocacy groups claim that smoking cannabis is a safe and effective treatment for various psychological and medical conditions, ranging from stress and anxiety to Alzheimer’s dementia and Parkinson’s disease, even though cannabis is not approved for such use by the Food and Drug Administration (FDA).

Legalization of cannabis is the process of removing all legal prohibitions against it. Cannabis would then be available to the adult general population for purchase and use at will, similar to tobacco and alcohol. Decriminalization is the act of removing criminal sanctions against an act, article, or behavior. Decriminalization of cannabis means it would remain illegal, but the legal system would not prosecute a person for possession under a specified amount. Instead, the penalties would range from no penalties at all, civil fines, drug education, or drug treatment.

No state has legalized cannabis thus far. It remains a US federally-controlled substance, which makes possession and distribution illegal. However, at the time of this writing, 26 states in the US have passed either medical cannabis laws, cannabis decriminalization laws, or both. See Table 1. A major concern of this commentary is that both the medicinal use of smoked cannabis plant and legalization/decriminalization of cannabis are being advocated in a way that circumvents the normal testing and regulatory processes by the FDA that is otherwise required for all drugs marketed for human use in the US. By circumventing this process, advocacy groups put state legislatures and/or voters in the position to decide on proposals with a certain impact on public health and medical treatment without necessarily being qualified to understand the pertinent scientific evidence.

Taking advantage of the obscure legal status of cannabis (i.e., federally banned illicit drug but approved by local governments for medical and/or recreational purposes), businesses involving sales of cannabis are flourishing and even stock-market investments are available. For example, CannabisInvestments.com provides information on ways one can invest in hemp-related and medical marijuana products and companies. These business interest groups are ratcheting pressure on state legislatures to decriminalize or medicalize cannabis, counting on support of millions of
addicted users and politicians looking for re-election votes and unaware of the dangers of such a legislative act.

**History and Legal Status of Cannabis**

Historically, cannabis has been used in various cultures and populations as indigenous therapy for a range of medical ailments (e.g., fever, insomnia, cachexia, headache, constipation, rheumatic pain) and diseases (e.g., venereal disease, malaria). Due to its presumed medical benefits, cannabis was recognized as an official, licit drug and listed in the U.S. Pharmacopoeia in 1850. Recreational use of cannabis surged in the 1930s during the Prohibition Era. In 1937, the Marijuana Tax Act effectively thwarted all cannabis use without criminalizing its possession or use. In 1970, the Controlled Substances Act classified cannabis as schedule I illicit drugs, the most restrictive category, and made possession a federal crime.

The Drug Enforcement Agency (DEA), which administers the Controlled Substances Act, continues to support the Schedule I assignment (and FDA concurred) noting that cannabis meets the three criteria for such placement under 21 U.S.C. 812(b):

1. high potential for abuse;
2. no currently accepted medical use in the US; and
3. lack of accepted safety for use under medical supervision.

A past evaluation by several Department of Health and Human Services (HHS) agencies, including FDA, Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute for Drug Abuse (NIDA), concluded that no sound scientific studies supported medical use of marijuana and no animal or human data supported the safety or efficacy of marijuana for general medical use.1

**Popular Perception of Cannabis Use**

In the public debate, cannabis has been considered a relatively benign recreational drug in comparison to opiates, stimulants, even alcohol. The favorable popular perception of cannabis presumably reflects the absence of dramatic physical signs of intoxication or withdrawal. Incidentally, cessation of cannabis use does cause withdrawal, but the severity is masked by the gradual release of delta 9-tetrahydrocannabinol (THC), the major psychoactive ingredient in cannabis, from fat tissue (adipocytes) where it accumulates during chronic use. The process is not unlike the tapering of medication during detoxification.

The general public has not been adequately informed about recent scientific findings demonstrating major adverse effects of smoking cannabis on physical and especially mental health, the latter varying in range from cognitive dulling, brief psychotic experiences, to long-term addiction and chronic psychosis.2,3

**Epidemiology of Cannabis Use and Addiction**

Cannabis (here referring to smoking of cannabis plants) is the most commonly used illicit drug in the US. Data from The National Survey on Drug Use and Health4,5 indicate that 44% of males and 35% of females have used marijuana at least once in their life time. More recent studies suggest that regular use of marijuana is increasing. Data from National Survey on Drug Use and Health4 indicate that in persons over the age of 12, the rate of past month cannabis use and the number of users in 2009 (6.6 percent or 16.7 million) were higher compared to 2008 (6.1% or 15.2 million) and 2007 (5.8% or 14.4 million).
Medicinal Use of Cannabinoids in Pill Form

Since THC was first isolated and purified\(^7\) from the cannabis plant in 1965, more than 400 chemicals have been isolated, approximately 60 of which are cannabinoids, compounds that are the active agents of cannabis. Reflecting a rapidly growing interest in the therapeutic potential of cannabis, about 21 cannabinoids are currently under study by the US FDA.\(^8\)

More recently, two types of cannabinoid receptors have been identified: CB1 found mostly in the central nervous system and responsible for psychoactive properties of cannabis, and CB2 found mostly in the spleen, immune tissues, and peripheral blood, and responsible for immunological and anti-inflammatory effects of cannabis.\(^9,10\) A group of endo-cannabinoids has been also identified, e.g., arachidonoylethanolamine or anandamide, as endogenous chemical modulators which mimic the actions of phytocannabinoids and activate cannabinoid receptors.\(^10\) These discoveries have led to the development of numerous CB receptor agonists and antagonists and numerous studies have tested therapeutic indications for these compounds. Medications containing natural or synthetic cannabinoids currently approved or being considered for approval for medicinal use are listed below:

Dronabinol (proprietary name Marinol), a synthetic THC, is FDA approved as an antiemetic in patients undergoing cancer chemotherapy, as an appetite stimulant for weight loss/decreased food intake in AIDS patients, and less frequently to augment analgesic treatment. Dronabinol is a Schedule III medication, indicating it has some potential for psychological and physical dependence.

Nabilone (proprietary name Cesamet), is a synthetic cannabinoid. FDA approved for peroral treatment of nausea and vomiting in chemotherapy patients who have not responded to conventional antiemetics, and anorexia and weight loss in patients with AIDS. Nabilone is a Schedule II medication, with high potential for mental health side effects and addiction.

Sativex, a liquid extract from cannabis plant, is used as oral spray (“liquid marijuana”), contains THC, cannabidiol (CBD), and other cannabinoids. Sativex has been approved for neuropathic pain, emesis, overactive bladder, and spasticity in several countries including England, Canada, and Spain. Phase III studies of Sativex are currently underway in the US, thus it does not have a schedule assigned to it.

These medications have been approved for specific indications (nausea, vomiting, cachexia) and are currently studied for a number of new indications, such as spastic syndromes, neurological disorders, neuropathic pain, and other pain syndromes, among others. Note that use of medications that have been tested and approved by the FDA is not controversial. What is objectionable is that current efforts to legalize cannabis crude plant use state legislative processes to bypass federal regulatory processes that were put in place specifically to protect the public health.

### Table 1

<table>
<thead>
<tr>
<th>State</th>
<th>Medical Cannabis</th>
<th>Decriminalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Arizona</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>California</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Colorado</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Delaware</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>DC</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Hawaii</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Maine</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Maryland</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Michigan</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Minnesota</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Mississippi</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Montana</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Nebraska</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Nevada</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>New Jersey</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>New Mexico</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>New York</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>North Carolina</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Ohio</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Oregon</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Vermont</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Washington</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
What is objectionable is that current efforts to legalize the cannabis crude plant use state legislative processes, and bypass federal regulatory procedures that were put in place specifically to protect the public health.
from a shorter gestation. The effects of maternal marijuana use on infant development have not been systematically studied. However, the lipid solubility of THC allows for rapid transit in breast milk, where it has been shown to accumulate and eventually pass to the newborn.

Carcinogenesis

Cannabis use increases the incidence of testicular germ cell tumors – TGCT. The authors observed a 70% increased risk of TGCT associated with current marijuana use, and the risk was particularly elevated for current use that was at least weekly or that began in adolescence. These associations were independent of known TGCT risk factors.

Effects of Smoked Cannabis on Mental Health

Smoking cannabis has a number of acute and chronic pathogenic effects on human mental health. Direct causal effects of chronic use are difficult to scientifically establish because the condition cannot be randomly assigned or manipulated experimentally for ethical reasons. Nevertheless, prospective population studies indicate that early cannabis use frequently serves as a prelude to other illicit drug use. Despite occasional non-confirmatory results, the “gateway sequence” is the most common pattern in the sequential progression in drug use, where marijuana use often is the initial step leading towards more powerful and more harmful drugs.

The mental effects of smoked cannabis include mental slowness, “relaxation”, tiredness, euphoria, and some users report anxiety and paranoia. Acute negative effects on cognition and performance, limited to periods of intoxication, have been well-documented. Long-term effects of cannabis use on cognitive performance involve subtle and selective impairments of specific higher cognitive functions including an impaired ability to focus attention and filter out irrelevant information, which is progressive with the cumulative duration of exposure to cannabis. These effects of chronic use recover only partially in ex-cannabis users, but the past duration of cannabis use continued to have an adverse effect on the ability to effectively reject complex irrelevant information.

Remodeling of Brain Reward Circuits

Cannabis Addiction

Active ingredients in cannabis, THC in particular, affect neurophysiological and behavioral systems in ways similar to addictive drugs. Cannabis use is associated with reinforcing pleasurable feelings of reward and euphoria either through direct effects on CB1 receptors expressed in N. Accumbens or through collateral circuits (including endogenous opiate receptors) with similar effects on the reward pathway in the brain. In most cases, addictive drugs “reset” the threshold for stimulation of the reward pathway at a higher level, where only supraphysiological stimulation by drugs can generate the desired feeling of reward. This “hijacking” of the reward pathway reduces the motivational power of natural rewards (e.g. food, opportunity to mate, relationships, etc) and thus reshapes normal motivational priorities. With repeated stimulation of this pathway, cannabis use induces neural plasticity and alters reward-based learning, all leading to phenomenological and behavioral features typical of addiction. Suggestive of its high addictiveness, cannabis is the most commonly used illicit drug in the US and rate of its use continues to rise.

Cannabis Use and Well-Being

Proponents of cannabis use argue that smoking cannabis provides relaxation and pleasure, enhances the sense of well being, contributes to stress-relief, and helps to deal with hard reality. Of course, any enhancement of well being of a mentally healthy person through use of a psychoactive substance is some sense an oxymoron. Furthermore, cannabis use decreases cortical dopamine which plays a major role in higher cognitive functions, working memory, executive function, etc. Hence, the “relaxed” feeling most cannabis users report as a desirable acute effect, in all likelihood reflects cognitive dulling (“amotivational syndrome”) caused by decreases in cortical dopamine. In other words, the weight of evidence indicates that cannabis creates cognitive dulling rather than reduction in anxiety, indifference rather than relaxation, and amotivation rather than inner peace, all closer to psychopathology than to well being.

Cannabis Use and Work Performance

There is an ongoing debate whether cannabis use interferes with people’s ability to work, relate to others, and/or live a normal life. Recent research clearly shows that any work that requires cognitive involvement and decision making is affected by cannabis use. In a study of young, otherwise mentally and physically healthy cannabis users, Wadsworth et al report an association between cannabis use and impairment in cognitive function and mood but not with workplace errors (although there was an association with lower alertness and slower response organization). Users experienced working memory problems at the start, and psychomotor slowing and poorer
episodic recall at the end of the work week. This highlights the importance of the timing of testing within the context and routine of everyday life. In a separate study of the same sample, cannabis use had a significant negative impact on safety at work (such as self-reported accidents), road traffic accidents, and minor injuries. Those who had higher levels of other risk factors associated with accidents and who also used cannabis were more likely to report an accident in the previous year. Thus, it is possible that cannabis-related effects were linked to an amplification of other risk factors associated with accidents and injuries.

Cannabis Use and Mental Health in the General Population

According to the study of 18,500 cannabis smokers published by Statistics Netherlands in October 2010, cannabis users suffer mental health problems twice as often as nonusers. The relative risk of mental problems was doubled in male and female cannabis users (20% and 28%, respectively) compared to male and female nonusers (10% and 14%, respectively). Most common mental health issues reported by cannabis users were anxiety, melancholy, sadness, and impatience. In contrast, physical health of users and nonusers barely differed. Though technically illegal, the Netherlands decriminalized the consumption and possession of less than 5 grams (0.18 ounces) of cannabis in 1976 under an official “tolerance” policy.

As an ophthalmologist specializing in glaucoma, I am sometimes asked by patients whether marijuana can be used to treat glaucoma. These patients have been made curious by provocative but incomplete, and often inaccurate, media reports suggesting the benefits of this form of treatment.

Glaucoma treatment involves lowering the intraocular pressure (IOP). This helps preserve visual function by slowing or halting progressive damage to the optic nerve. Smoking or ingesting marijuana can, indeed, lower the IOP.

In addition, THC (marinol), the major psychoactive ingredient in marijuana, has been shown to have an IOP-lowering effect when ingested orally. However, due to a variety of factors, it is not possible to transform these observations into a widespread and clinically useful method of glaucoma treatment at the present time.

The pressure-lowering effects of inhaled marijuana are variable and of short duration. To achieve continuous IOP lowering, this short duration of action requires smoking marijuana every three to four hours. The accompanying article describes the cognitive and systemic side effects of regular marijuana use. These side effects proscribe the continuous use of marijuana as a practical way to treat glaucoma.

There might theoretically exist a very rare patient with end-stage glaucoma in whom all methods of medical and surgical treatment have either failed or are contraindicated. Perhaps in this hypothetical isolated case smoking marijuana can be considered. However, I have never advised this method of treatment, and I have never spoken with an ophthalmologist who has recommended this. Inhaled marijuana compares poorly to the eye drops we have available to lower IOP. Currently available glaucoma eye drops have been extensively studied and are usually well tolerated and effective. They have a much longer duration of action when compared to inhaled marijuana. A variety of laser and incisional surgical techniques, both established and recently developed, are also available.

Marijuana has a complex composition, containing 60 known cannabinoid compounds. Study of these compounds is ongoing, and it may well be that one or more of these compounds will become a valuable method of glaucoma treatment. At the present, however, despite public fascination with the concept, smoking marijuana as a way to treat glaucoma is not well established or practical, and may be a dangerous option.

References
3. Primary Open-Angle Glaucoma: Medical Therapy and Surgery. From the American Academy of Ophthalmology Preferred Practice Patterns, November 2010

Charles Lederer, MD, MSMA member since 1982, is a Glaucoma Specialist in Kansas City, Missouri, and the Missouri Medicine Editorial Board member in Ophthalmology.
of poly-drug use or neurologic/mental disorders. Cannabis users had bilaterally and significantly reduced hippocampal and amygdala volumes, with changes greater in the hippocampus. In fact, left hemisphere hippocampal volume was inversely associated with cumulative exposure to cannabis during the previous 10 years as well as with subthreshold positive psychotic symptoms. Positive psychosis symptom scores were also associated with cumulative exposure to cannabis.

Cannabis Use and the Risk of Schizophrenia, Psychosis, and Affective Disorders

Cannabis use is among the environmental factors associated with increased risk and worsened prognosis of schizophrenia and some data suggest a causal effect. Cannabis use also is associated with more prevalent expressions of a wider psychosis phenotype. Isolated psychotic symptoms have reported prevalences of 5–15% among chronic cannabis users. Although causality remains difficult to infer from observational studies, the weight of the evidence appears to favor a causal contribution from cannabis use for the development of Schizophrenia and psychosis.

Recent meta-analyses lend further support to the hypothesis that cannabis use causally contributes to the increased risk of development of schizophrenia. In a comprehensive and systematic meta-analysis, Moore et al determined whether cannabis use contributes causally to the development of nonsubstance psychiatric illness, such as schizophrenia and affective disorders. The study was designed to address as much as possible two of the most important methodological problems in studying the relation between cannabis use and psychosis: 1) the potential for reverse causality (where psychosis causes...
cannabis use and not vice versa) and 2) the transitory intoxication effects (that is misinterpreted as psychosis as the false positive error). The results indicated that the risk of psychosis is increased by roughly 40% (pooled adjusted OR: 1.41) in cannabis users. The results were not as impressive for affective disorders. Within the users, a dose-response effect was observed with the risk more than doubled (OR = 2.1) in the most frequent users. For cannabis and psychosis, there was evidence of confounding effects, but the associations persisted in almost all studies, even after adjustment for comprehensive lists of variables. The authors concluded that “there is now sufficient evidence to warn young people that using cannabis could increase their risk of developing a psychotic illness later in life” (page 319).

In a meta analysis of peer-reviewed publications in English reporting age at onset of psychotic illness in substance using and non–substance using groups Large et al18 found an association between cannabis use and earlier onset of psychosis (the effect was not seen with alcohol). The authors suggest the need for renewed warnings about the potentially harmful effects of cannabis. Similar findings are reported by other authors.19

Genetic Moderation of Cannabis Effect on Psychosis

One of the most puzzling aspects of cannabis-associated psychosis is that schizophrenia is not rising in incidence to reflect prevalent cannabis use. The likely answer is that there is variation in individual sensitivity to the psychosis-inducing effects of cannabis. In other words, individuals who have a greater biological vulnerability to psychosis are more likely to develop psychotic experiences when exposed to cannabis. As an example, the COMT Val/Val genotype is a risk factor for schizophrenia in the general population40 presumably by providing a pathological substrate, such as low dopamine in the frontal cortex40 and high mesolimbic dopamine.41 Both conditions are believed to contribute to schizophrenia symptoms. Carriers of the COMT Val/Val genotype have low cortical dopamine but do not automatically develop schizophrenia. Rather, this genotype is considered to be a matter of individual variability in the level of cortical dopamine. However, carriers of this genotype, who were also chronic cannabis users as adolescents, have a dramatically (up to 10 times) higher risk of psychosis42 compared to adult-onset cannabis users with the same genotype. Cannabis use is reported to further decrease cortical8 and increase mesolimbic dopamine41 possibly amplifying the preexisting, genetically created dopamine deficit. If occurring during the sensitive developmental period of adolescence, such augmentation may synergistically facilitate the onset of psychosis. Similar interactive synergism was recently described for the AKT1 gene and cannabis.41

Finally, recent study by Welch et al44 was the first longitudinal study to demonstrate an association between thalamic volume loss and exposure to cannabis in people currently unaffected by Schizophrenia but with increased risk for the illness due to positive family history. As Welch et al conclude, this finding may be important in understanding the link between cannabis exposure and the subsequent development of Schizophrenia.

Conclusion

Empirical and clinical studies reviewed here clearly demonstrate pathological effects of cannabis smoking on physical and especially mental health as well as its interference with social and occupational functioning. We did not find a single methodologically sound study to suggest that the benefits of smoking cannabis outweigh the associated risks. These negative data far outweigh documented benefits for a limited set of medical indications for which safe and effective alternative treatments are readily available. However, advocacy groups are pursuing legalization or medical use of smoked cannabis, largely ignoring pills containing extracted THC and other cannabinoids. It appears therefore that it is not the benefit of active cannabis ingredients, but the route of administration, a wider set of indications, and the ritual of use that’s being advocated. Based on the empirical and clinical evidence reviewed here, it seems safe to conclude that, if there is any medical role for cannabinoid drugs, it lies with chemically modified extracts, not with unprocessed cannabis plant.

References
1. FDA Press Office , 2006
3. van Os, J., Kenis, G., Ratten, B.P. The environment and schizophrenia, Nature 2010; 468 (7321): 203-12


44. van Winkel R, GROUP Investigators. Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis Archives of General Psychiatry 2011; Epub 1521–1527.